pentobarbital will decrease the level or outcome of roflumilast by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not advised; potent cytochrome P450 enzyme inducers minimize systemic publicity to roflumilast and may lessen the therapeutic effectivenessThe typical every day dose to the barbiturate addict